Invitae Corporation
8
3
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.5%
1 terminated/withdrawn out of 8 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
Role: collaborator
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Role: collaborator
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
Role: lead
Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel
Role: lead
Universal Germline Testing in the Community
Role: lead
ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
Role: lead
PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients
Role: lead
A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy
Role: collaborator
All 8 trials loaded